Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study

• Published in: Rheumatic & musculoskeletal diseases open Vol. 7; no. 2; p. e001600
• Main Authors: Mease, Philip J, Landewé, Robert, Rahman, Proton, Tahir, Hasan, Singhal, Atul, Boettcher, Elke, Navarra, Sandra, Readie, Aimee, Mpofu, Shephard, Delicha, Eumorphia Maria, Pricop, Luminita, van der Heijde, Desirée
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.07.2021; BMJ Publishing Group
• Series: Original research
• Subjects: Adult; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized; Arthritis; Arthritis, Psoriatic - diagnostic imaging; Arthritis, Psoriatic - drug therapy; Clinical medicine; Cytokines; Disease Progression; Double-Blind Method; Humans; Monoclonal antibodies; Patients; Psoriasis; Psoriatic Arthritis; Rheumatology; Tumor necrosis factor-TNF; psoriatic; cytokines; arthritis; inflammation; biological therapy
• DOI: 10.1136/rmdopen-2021-001600
• ISSN: 2056-5933

ObjectiveSecukinumab provided sustained efficacy, low radiographic progression and consistent safety over 52 weeks in patients with psoriatic arthritis (PsA) in the FUTURE 5 study. Here, we report 2-year (end-of-study) results from this study.MethodsAdults with active PsA were randomised 2:2:2:3 to receive subcutaneous secukinumab 300 mg load (300 mg), 150 mg load (150 mg), 150 mg no load or placebo at baseline; weeks 1, 2, 3 and 4; and every 4 weeks thereafter. Secukinumab could be escalated from 150 mg to 300 mg starting at week 52, if active signs of disease were observed based on physician’s assessment. Assessments at week 104 (2 years) included clinical end points and radiographic damage (mean change in van der Heijde-modified total Sharp score (vdH-mTSS)). Safety analysis included all patients who received ≥1 dose of study medication.ResultsOf the 996 patients randomised, 783 patients (78.6%) completed 2 years of treatment. Improvement in clinical end points was sustained through 2 years. The vdH-mTSS (mean change (SD)) was 0.10 (1.74; 300 mg), 0.52 (2.66; 150 mg) and 0.41 (2.20; 150 mg no load) at 2 years. The proportion of patients with no radiographic progression (change from baseline in vdH-mTSS ≤0.5) at 2 years was 89.5% (300 mg), 82.3% (150 mg) and 81.1% (150 mg no load).ConclusionSecukinumab with and without loading regimen provided sustained clinical efficacy and low radiographic progression through 2 years in patients with PsA. No new safety findings were reported.Trial registration numberNCT02404350.